These data suggest that combination of CD73 blockade and targeting of 4-1BB or other costimulatory molecules augments the number of effector CD8+ T cells, leading to a qualitatively more effective anti-tumor T cell response against the growth of established tumors. The gene discussed is CD8A; the disease is neoplasm.